Related Experiment Videos
Fluoxetine hydrochloride (Prozac)-induced pulmonary disease
R J Gonzalez-Rothi1, D S Zander, P R Ros
1Department of Medicine, University of Florida College of Medicine, Gainesville, USA.
Chest
|June 1, 1995
Summary
Fluoxetine hydrochloride (Prozac) may cause lung damage, including hypersensitivity pneumonitis and phospholipidosis, leading to progressive dyspnea and restrictive lung disease. This case highlights potential pulmonary risks associated with this common antidepressant.
Area of Science:
- Pulmonary Medicine
- Toxicology
- Pharmacology
Background:
- Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), are widely prescribed.
- Drug-induced lung injury is a recognized but often underdiagnosed complication of pharmacotherapy.
- Fluoxetine hydrochloride is a commonly used SSRI for treating depression and other mood disorders.
Observation:
- A patient presented with worsening shortness of breath (dyspnea) and abnormal findings on lung imaging (infiltrates).
- The patient exhibited signs of restrictive lung disease, indicating reduced lung capacity.
- These respiratory symptoms emerged during treatment with fluoxetine hydrochloride (Prozac).
Findings:
- Pathological examination of lung tissue revealed findings consistent with hypersensitivity pneumonitis.
- Hypersensitivity pneumonitis is an immune-mediated inflammatory lung disease.
- Additionally, the lung tissue showed evidence of phospholipidosis, an accumulation of phospholipids.
Implications:
- This case suggests a potential causal link between fluoxetine hydrochloride and severe pulmonary toxicity.
- Physicians should consider drug-induced lung disease in patients on fluoxetine presenting with unexplained respiratory symptoms.
- Further investigation into the mechanisms of fluoxetine-induced lung injury is warranted.